newsfilter
← Latest News
GlobeNewswire·

Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG

– Novartis to acquire Tourmaline Bio for $48.00 per share in cash for a total equity value of approximately $1.4 billion – – Transaction reflects the potential of Tourmaline's pacibekitug, a long-acting, fully-human,